Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomized, phase 3 trial - The Lancet expert reaction to ACHIEVE-3 trial results about efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes | Science Media Center A research team led by Julio Rosenstock, an endocrinologist at the University of Texas Southwestern Medical Center, and Daisuke Yabe of the Kyoto University Graduate School of Medicine, published the results of a Phase III trial comparing the oral GLP-1 drug orfoglipron, manufactured by Eli Lilly, with oral semaglutide tablets in adult type 2 diabetes patients with inadequate blood sugar control while being treated with metformin, one of the first medications prescribed to those diagnosed with type 2 diabetes
Consider holding your next dose and contacting your provider if severe symptoms develop
Glutathione, Cysteine, and the Neuromelanin Pathway: Potential Roles in the Pathogenesis of Parkinson's Disease - a New Hypothesis Glenn Dryhurst 16
Statistical analysis Quantitative variables without a normal distribution were expressed as median and IR and comparisons were carried out using the MannWhitney test for non-related samples and Wilcoxon test for related samples
Trials also enroll smaller, more controlled populations over shorter time windows
